Genmab — Regulatory Filings 2007

Aug 2, 2007

Genmab A/S Toldbodgade 33 1253 Copenhagen K Denmark Tel + 45 7020 2728 Fax + 45 7020 2729

Contact:

Helle Husted Sr. Director, Investor Relations T: +45 33 44 77 30 M: +45 25 27 47 13 E: hth@genmab.com

GENMAB REGAINS RIGHTS TO HUMAX-TAC

Summary: Genmab has regained all rights to HuMax-TAC from Merck Serono S.A.

Copenhagen, Denmark; August 2, 2007 – Genmab A/S (OMX: GEN) announced today it has regained all rights to the HuMax-TAC™ antibody from Merck Serono following a portfolio review by Merck Serono. Worldwide rights to HuMax-TAC were previously licensed to Merck Serono in May 2005. Regaining the rights to HuMax-TAC will not influence Genmab's financial guidance for 2007.

"Now that we have regained rights to the HuMax-TAC program, Genmab will review the program internally to decide on future plans," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

About Genmab A/S

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody™, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. For more information about Genmab, visit www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our

GENMAB REGAINS RIGHTS TO HUMAX-TAC

relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD4®; HuMax-CD20®; HuMax-EGFr™; HuMax-Inflam™; HuMax-TAC™; HuMax-HepC™; HuMax-CD38™; HuMax-ZP3™; and UniBody™ are all trademarks of Genmab A/S.

###